Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
5,377,516
-
Shares change
-
-332,320
-
Total reported value, excl. options
-
$32,048,000
-
Value change
-
-$2,510,463
-
Number of buys
-
5
-
Number of sells
-
-10
-
Price
-
$5.9
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2016
26 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q2 2016.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,377,516 shares
of 77,331,078 outstanding shares and own 6.95% of the company stock.
Largest 10 shareholders include BVF INC/IL (1,775,572 shares), Capital World Investors (1,030,000 shares), Invesco Private Capital, Inc. (436,384 shares), PERCEPTIVE ADVISORS LLC (432,800 shares), Opaleye Management Inc. (410,000 shares), ROYAL BANK OF CANADA (392,484 shares), Point72 Asset Management, L.P. (358,531 shares), DAFNA Capital Management LLC (214,091 shares), Novo A/S (127,563 shares), and State of New Jersey Common Pension Fund D (65,000 shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.